Clinical trials: Metastatic Leiomyosarcoma

Leiomyosarcoma

Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)

• Unknown status
• Age: 16 to 100 years
• Phase 2

The present study is an open-label, randomized, controlled, two-arm multi-center study of the efficacy of L19TNF treatment in combination with doxorubicin versus doxorubicin alone in metastatic leiomyosarcoma patients.

Trial name

FIBROSARC US (NCT03420014)

Testing

Doxorubicin, L19TNF plus doxorubicin

Where

8 sites in United States

Volunteers

114 people

Sponsor

Philogen S.p.A.